What Sets Exilby Apart from Prescription Cannabis
Exilby is a standardized, THC-rich full-spectrum extract from the cannabis plant. Unlike previous prescriptions for cannabis flowers or extracts compounded by pharmacies, Exilby is dispensed as an approved finished pharmaceutical with defined dosing. This distinction is crucial. With compounded prescriptions, the treating physician bears responsibility for the specific composition. An approved finished medicine, by contrast, has undergone a complete regulatory review process with demonstrated efficacy and safety.
📑 Inhaltsverzeichnis
Prior to Exilby, Germany had only one comparably regulated product: Sativex. For those interested in the history of this pharmaceutical class, our article on Sativex, the first cannabis-based finished medicine provides detailed background. For information on how regular prescription cannabis flowers and extracts work, our guide Cannabis by Prescription explains the process in detail.
The Clinical Evidence Behind Approval
The approval is based on a Phase 3 program involving more than 1,200 patients. In the key efficacy study with 820 participants, Exilby reduced pain intensity by 1.9 points on the scale used. Under placebo, the reduction was 1.4 points. At first glance, the 0.5-point difference appears modest, but in the pre-defined target population, the difference versus placebo was 1.6 points. Beyond pain relief alone, sleep quality, physical function, and overall quality of life also improved.
Particularly relevant for this indication is another finding: the studies demonstrated no detectable dependence potential, which distinguishes Exilby from classical opioids. Approximately 17 percent of participants discontinued treatment due to adverse effects. The fact that a plant-derived full extract shows measurable efficacy for chronic pain aligns with observations from other controlled trials. Our article on a randomized trial of cannabis for fibromyalgia, rheumatoid arthritis, and osteoarthritis offers further insight.
Significance for Patients and the Industry
Market launch is planned for September 2026 in Germany and Austria. For patients suffering from chronic back pain, this creates a treatment option that bridges conventional pain medications and individualized cannabis prescriptions. Older patients in particular, where chronic pain is common, could benefit from a standardized product. Our article on cannabis for seniors explores the opportunities and risks to consider.
The approval comes during a politically tense phase. While lawmakers debate stricter regulations for prescribing and distributing cannabis flowers, the class of approved finished pharmaceuticals is simultaneously becoming established. A tested medicine with solid clinical data is far more difficult to challenge from a regulatory standpoint than flower prescriptions. Vertanical has also announced plans to investigate the active ingredient for additional indications such as polyneuropathy and arthritis. Should these efforts succeed, a single product could evolve into an entire product line.
Frequently Asked Questions
What exactly is Exilby?
Exilby is a cannabis-based finished pharmaceutical from Munich-based company Vertanical. It contains a standardized, THC-rich full-spectrum extract and is approved for treating chronic back pain with a neuropathic component.
When will Exilby be available in Germany?
BfArM approval was granted on June 9, 2026. Market launch is planned for September 2026 in Germany and Austria. Only from that point forward can the medicine be ordered through pharmacies.
How does Exilby differ from prescription cannabis?
With prescription cannabis, physicians order flowers or extracts as individual compounded formulations. Exilby, by contrast, is an approved finished pharmaceutical with standardized dosing that has undergone a complete regulatory review demonstrating efficacy and safety.
Is Exilby habit-forming?
The Phase 3 studies showed no detectable dependence potential. This distinguishes the medicine from many classical opioids used for chronic pain. Adverse effects nonetheless led approximately 17 percent of participants to discontinue treatment.
What conditions is Exilby approved for?
Approval covers chronic back pain with a neuropathic component. The manufacturer is also investigating additional indications such as polyneuropathy and arthritis, though these do not yet have regulatory approval.
Würdest du bei chronischen Rückenschmerzen ein Cannabis-Arzneimittel wie Exilby nehmen?
Sources: Bloomberg, ad-hoc-news, Pharmazeutische Zeitung, BfArM, Vertanical (as of June 13, 2026).
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
